

Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

TERAFORCE TECHNOLOGY CORP

Form 10-Q

May 15, 2003

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

-----

FORM 10 - Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2003

Commission File Number 0-11630

-----

TERAFORCE TECHNOLOGY CORPORATION  
(Exact Name of Registrant as Specified in Its Charter)

DELAWARE (State or Other Jurisdiction of Incorporation or Organization)	76-0471342 (I.R.S. Employer Identification No.)
1240 EAST CAMPBELL ROAD, RICHARDSON, TEXAS (Address of Principal Executive Offices)	75081 (Zip Code)

469-330-4960  
(Registrant's Telephone Number, Including Area Code)

-----

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes  No

There were 118,422,183 shares of Common Stock outstanding as of April 30, 2003.

=====

TERAFORCE TECHNOLOGY CORPORATION AND SUBSIDIARIES

# Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

## INDEX

		PAGE
-----		
PART I	FINANCIAL INFORMATION	
ITEM 1	FINANCIAL STATEMENTS	
	Consolidated Balance Sheets of the Company at March 31, 2003 (unaudited) and December 31, 2002	2
	Consolidated Statements of Operations of the Company (unaudited) for the three months ended March 31, 2003 and 2002	3
	Consolidated Statements of Cash Flows of the Company (unaudited) for the three months ended March 31, 2003 and 2002	4
	Notes to Consolidated Financial Statements	5
ITEM 2	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	8
ITEM 3	QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK	11
ITEM 4	CONTROLS AND PROCEDURES	11
PART II	OTHER INFORMATION	12
ITEM 2	CHANGES IN SECURITIES AND USE OF PROCEEDS	12
ITEM 6	EXHIBITS AND REPORTS ON FORM 8-K	12
	SIGNATURES	14
	CERTIFICATIONS	15

### PART I - FINANCIAL INFORMATION

#### ITEM 1 - FINANCIAL STATEMENTS

TERAFORCE TECHNOLOGY CORPORATION AND SUBSIDIARIES  
Consolidated Condensed Balance Sheets  
(Thousands of dollars, except share data)

	March 31, 2003	December 2002
-----		
Assets	(unaudited)	-----
Current assets:		

Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

Cash and cash equivalents	\$	5	\$	5
Temporary cash investments		--		45
Accounts receivable		499		57
Receivables from affiliate		699		69
Inventories		2,347		2,35
Prepaid services		74		19
Prepaid expenses and other current assets		746		58
		-----		-----
Total current assets		4,370		4,91
Property and equipment, net		517		57
Investment in affiliate		485		70
Other assets		1,276		53
		-----		-----
	\$	6,648	\$	6,72
		=====		=====
Liabilities and Stockholders' Deficit				
Current liabilities:				
Notes payable	\$	5,547	\$	4,04
Accounts payable		2,071		1,91
Accrued liabilities		1,612		1,39
		-----		-----
Total current liabilities		9,230		7,35
Long-term notes payable		--		90
Other long-term liabilities		975		1,10
Stockholders' deficit:				
Common Stock, \$.01 par value; authorized 200,000,000 shares; 118,422,183 and 114,255,518 shares issued in 2003 and 2002, respectively		1,184		1,14
Additional paid-in capital		186,180		184,95
Accumulated deficit		(189,334)		(187,14
		-----		-----
		(1,970)		(1,04
Less 400,474 shares of common stock in treasury at cost		(1,587)		(1,58
		-----		-----
Total stockholders' deficit		(3,557)		(2,63
		-----		-----
	\$	6,648	\$	6,72
		=====		=====

See accompanying notes to consolidated condensed financial statements.

Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

	Three Months Ended March 31,	
	2003	2002*
	----- (unaudited) -----	
Net revenue	\$ 953	\$ 1,630
Cost of revenue	680	759
	-----	-----
Gross profit	273	871
	-----	-----
Expenses:		
Engineering and development	785	1,037
Selling and administrative	1,204	1,185
	-----	-----
	1,989	2,222
	-----	-----
Operating loss	(1,716)	(1,351)
	-----	-----
Other income (expense):		
Litigation settlement	--	6,300
Litigation costs	(77)	(52)
Share of income (loss) of unconsolidated affiliate	(217)	30
Interest expense	(116)	(143)
Interest income and other	(65)	--
	-----	-----
	(475)	6,135
	-----	-----
Net income (loss)	\$ (2,191)	\$ 4,784
	=====	=====
Basic and diluted income (loss) per share	\$ (0.02)	\$ 0.06
	=====	=====
Weighted average number of common shares outstanding -		
Basic and diluted	115,054	86,688
	=====	=====

\*Certain amounts have been reclassified to conform to current classifications.

See accompanying notes to consolidated condensed financial statements.

Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

	----- 2003 -----	2002 ----- (unaudited)
Cash flows from operating activities:		
Net income (loss)	\$(2,191)	\$ 4,78
Adjustments to reconcile net income (loss) to net cash used in operating activities:		
Litigation settlement	--	(6,30)
Utilization of prepaid services	119	30
Depreciation and amortization	65	5
Share of loss (income) from unconsolidated affiliate	217	(3
Other	(181)	8
Change in operating assets and liabilities:		
Accounts receivable	74	
Inventories	6	23
Accounts payable and accrued liabilities	371	(1,71
	-----	-----
Net cash used in operating activities	(1,520)	(2,58
	-----	-----
Cash flows from investing activities:		
Proceeds from litigation settlement	--	6,30
Capital expenditures	(4)	(5
Net proceeds from disposal of discontinued operations	--	1,37
Software development costs	(83)	-
Temporary cash investments	457	-
	-----	-----
Net cash provided by investing activities	370	7,61
	-----	-----
Cash flows from financing activities:		
Proceeds from issuance of notes payable	600	50
Proceeds from issuance of common stock	500	-
Principal payments on notes payable	--	(1,35
	-----	-----
Net cash provided by (used in) financing activities	1,100	(85
	-----	-----
Net increase (decrease) in cash and cash equivalents	(50)	4,18
Cash and cash equivalents, beginning of period	55	-----
	-----	-----
Cash and cash equivalents, end of period	\$ 5	\$ 4,18
	=====	=====

See accompanying notes to consolidated condensed financial statements.

## Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

### BASIS OF PRESENTATION

The accompanying consolidated financial statements have been prepared by the Company without audit in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included.

The accompanying consolidated financial statements do not include certain footnotes and financial presentations normally required under accounting principles generally accepted in the United States of America and, therefore, should be read in conjunction with the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2002.

The Company incurred an operating loss in the first quarter of 2003 and has incurred significant operating losses in 2002, 2001 and 2000. These losses were funded by proceeds from the issuance of equity securities and notes payable, and as of March 31, 2003 notes payable due within one year amounted to \$5,547,000. The Company's continued existence is dependent on the Company's ability to continue to fund any operating losses and on the restructuring or refinancing of its debt obligations. In the first quarter of 2003 the Company has generated additional capital amounting to \$1,500,000 from the sale of equity securities and from the proceeds of new credit facilities. In addition, the Company is engaged in continuing discussions regarding additional sources of capital, as well as the restructuring of its outstanding debt obligations.

The Company's operating losses have declined over the three year period ended December 31, 2002 primarily as a result of the disposal of certain operations, specifically those related to the telecommunications industry, the reduction of other operating expenses and increases in net revenues from the Company's defense electronics business. Net revenues from the sale of defense electronics products have increased in each of the last three years and management expects net revenues to increase further in 2003. Therefore, management believes that the Company's needs for capital to fund operating losses will continue to decline.

The Company believes that it will be able to fund any further operating losses and to refinance or otherwise restructure its outstanding debt obligations through either the issuance of new equity securities, the incurrence of new debt or the modification of the terms of its existing debt obligations. There can be no assurance that the Company can accomplish these matters, or can do so under acceptable terms. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

### INVENTORIES

The components of inventories are as follows:

Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

	March 31, 2003	December 31, 2002
	-----	-----
	(\$ Thousands)	
Raw materials	\$ 1,628	\$ 1,658
Work in process	423	408
Finished goods	296	288
	-----	-----
Total	\$ 2,347	\$ 2,354
	=====	=====

SEGMENTS OF BUSINESS

In the three-month periods ended March 31, 2003 and 2002, all of the Company's net revenues were generated from its defense electronics business.

Segment-specific margins (gross profit less total engineering and development costs, including capitalized software for the segment):

	Three Months Ended March 31,	
	2003	2002
	-----	-----
	(\$ Thousands)	
Defense electronics	\$ (512)	\$ 97
Optical networking equipment	--	(101)
Other	--	(162)
	-----	-----
Subtotal segment specific	(512)	(166)
All other expenses	(1,204)	(1,185)
	-----	-----
Operating loss	\$ (1,716)	\$ (1,351)
	=====	=====

Assets identifiable only by combined segments:

	At March 31, 2003	At December 31, 2002
	-----	-----
	(\$ Thousands)	
Defense electronics	\$ 3,834	\$ 3,760
Optical networking equipment and other	1,233	1,501
Not allocable to a segment	1,581	1,463
	-----	-----
Total	\$ 6,648	\$ 6,724
	=====	=====

INCOME TAXES

For the three months ended March 31, 2003 and 2002, the Company's

## Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

effective income tax rate differed from the federal statutory rate due to current period tax expense offset by an offsetting change in the valuation allowance for the same amount.

6

TERAFORCE TECHNOLOGY CORPORATION  
Notes to Consolidated Condensed Financial Statements  
(Unaudited)  
March 31, 2003

### STOCK OPTION PLAN

The Company accounts for its stock option plan in accordance with the provisions of Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees," and related interpretations. As such, compensation expense is recorded on the date of grant only if the current market price of the underlying stock exceeded the exercise price. SFAS No. 123, "Accounting for Stock-Based Compensation," requires pro forma net income and pro forma earnings per share disclosures for employee stock option grants as if the fair-value-based method defined in SFAS No. 123 had been applied.

	Three Months Ended March 31,	
	2003	2002
Net income (loss) allocable to common shareholders:		
As reported	\$ (2,191)	\$ 4,784
Pro forma	\$ (2,360)	\$ 4,645
Income (loss) per share:		
As reported	\$ (0.02)	\$ 0.06
Pro forma	\$ (0.02)	\$ 0.05

### EARNINGS PER SHARE

Basic and diluted earnings per share are the same for the three months ended March 31, 2003 and 2002 because all potential common shares were anti-dilutive for those periods.

### STOCKHOLDERS' EQUITY

In January and March 2003, the Company completed private placement transactions in which it issued a total of 4,166,667 shares of common stock and warrants for the purchase of an additional 4,333,333 shares of common stock for aggregate proceeds of \$500,000. The warrants have an exercise price of \$0.15 per share and are exercisable at any time through March 31, 2007.

In March 2003, the Company and its wholly-owned subsidiary, DNA Computing Solutions, Inc. ("DNA-CS"), entered into a revolving line of credit with a bank in order to provide working capital to DNA-CS. Under the facility, DNA-CS may borrow up to \$1,000,000. Outstanding amounts are due March 26, 2004; however, DNA-CS may extend such date six months, provided certain conditions are



## Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

maintained. Interest is payable monthly at the greater of prime plus 1% and 5.25%. At March 31, 2003, \$600,000 was outstanding under this facility.

This working capital facility is secured by the accounts receivable and inventory of DNA-CS, the guarantee of the Company and by limited guarantees provided by certain private investors. As consideration for providing the guarantees that secure the Notes the Company has entered into a Reimbursement Agreement with the guarantors. The Reimbursement Agreement provides that the Company will reimburse the investors for any amounts that they may be required to reimburse the bank pursuant to the guarantees. Pursuant to the Reimbursement Agreement and related agreements,

7

TERAFORCE TECHNOLOGY CORPORATION  
Notes to Consolidated Condensed Financial Statements  
(Unaudited)  
March 31, 2003

as of March 26, 2003 the investors have the right to purchase up to 8,333,333 shares of the Company's common stock for \$1,000,000 in cash, the proceeds of which will be used to repay amounts outstanding under the Note and provide for the release of the guarantees. In addition, as of March 26, 2003 the investors received warrants to purchase an aggregate of 9,583,333 shares of the Company's common stock at a price of \$0.15 per share. The warrants may be exercised at any time through March 31, 2007. The Company has valued the warrants at approximately \$360,000, using the Black-Scholes pricing model. This amount and beneficial conversion feature in the amount of approximately \$408,000 related to the purchase rights have been recorded as deferred financing costs.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE PERIOD ENDED MARCH 31, 2003

Forward Looking Statement

This Quarterly Report on Form 10-Q contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this report, as well as in oral statements made by the Company, statements that are prefaced with the words "may," "will," "expect," "anticipate," "believe," "continue," "estimate," "project," "intend," "designed" and similar expressions are intended to identify forward-looking statements regarding events, conditions and financial trends that may affect the Company's future plans, business strategy, results of operations, financing activities and financial position. These statements are based on the Company's current expectations and estimates as to prospective events and circumstances about which the Company can give no firm assurance. Further, any forward-looking statement speaks only as of the date the statement was made, and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date the statement was made. Because it is not possible to predict every new factor that may emerge, forward-looking statements should not be relied upon as a prediction of actual future financial condition or results. Examples of types of forward looking statements include statements on future levels of net revenue and cash flow, new product development, strategic plans and financing. These forward -looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Factors that might cause such a difference include, but are not limited to: general economic conditions in the markets the Company operates in; the ability of the Company to execute its plan in strategic direction; success in the development

## Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

and market acceptance of new and existing products; dependence on suppliers, third party manufacturers and channels of distribution; customer and product concentration; fluctuations in customer demand; the ability to obtain and maintain access to external sources of capital; the ability to control costs; overall management of the Company's expansion; and other risk factors detailed from time to time in the Company's filings with the Securities and Exchange Commission. The terms "we," "our" and "us" and similar terms refer to the Company and its consolidated subsidiaries, not to any individual or group of individuals.

---

### COMPARISON OF FIRST QUARTER 2003 TO FIRST QUARTER 2002

---

#### NET REVENUE

For the first quarter of 2003 and 2002 all of our net revenues were generated by our defense electronics business. Net revenue from defense electronics decreased 42% in the first quarter of 2003 as compared to the first quarter of 2002. However, in the first quarter of 2003 the Company's bookings of new orders amounted to approximately \$4,000,000 and the Company's backlog of orders amounted to approximately \$3,200,000 at March 31, 2003, compared to a backlog of approximately \$500,000 at March 31, 2002. The decline in net revenues in the first quarter of 2003 is due, in part, to the timing of shipments based on customer requirements. In addition, due to our increased working capital needs related to the increase in orders and unexpected delays in completing financing arrangements in the first quarter of 2003, we experienced delays in payments to some of our vendors. These delays temporarily affected our ability to complete orders. Management believes that the financing arrangements that have been concluded and that are being negotiated will alleviate the liquidity difficulties and that revenues during the balance of 2003 will increase as compared to 2002.

8

#### GROSS PROFIT

Gross profit from defense electronics decreased in the first quarter of 2003 as compared to the first quarter of 2002 due to the decline in net revenues between these periods.

#### ENGINEERING AND DEVELOPMENT EXPENSE

Engineering and development expense decreased 33% to \$785,000 in the first quarter of 2003 from \$1,037,000 in the same period in 2002. Costs by product line are as follows:

	Three Months Ended March 31,	
	2003	2002
	(\$ Thousands)	
Defense electronics	\$ 785	\$ 774
Optical networking products	--	101
Other	--	162
	-----	-----
	\$ 785	\$ 1,037

=====

Engineering and development expenses related to defense electronics in the first quarter of 2003 reflect on-going enhancements of the VQG4 product line and our new Eagle product that was introduced at the end of the first quarter of 2003. All development activities, other than those related to our defense electronic products, were terminated in 2002. Included in engineering and development expenses during the first quarter of 2003 and 2002 is approximately \$119,000 and \$300,000, respectively, related to design services provided by Flextronics International, Ltd. These services are provided under the engineering design services agreements we entered into when we sold our engineering design services business in January 2002.

SELLING AND ADMINISTRATIVE EXPENSE

Selling and administrative expenses increased less than 2% in the first quarter of 2003 as compared to the first quarter of 2002.

LITIGATION SETTLEMENT

In March 2002 we settled our outstanding litigation against Cadence Design Systems, Inc. We received \$6,300,000, net of attorney fees, from this settlement.

LITIGATION COSTS

Litigation costs represent legal fees and expenses related to the shareholder action.

INTEREST EXPENSE

Interest expense decreased by \$27,000 in the first quarter of 2003 as compared to the first three months of 2002 because of decreased borrowings and lower interest rates.

-----  
LIQUIDITY AND CAPITAL RESOURCES  
-----

As of March 31, 2003 our working capital deficit was \$4,860,000, which included \$5,547,000 of notes payable due within one year. Of these amounts, approximately \$1,600,000 is due on demand or by June 30, 2003. At March 31, 2003 we had \$400,000 available for borrowing under a revolving bank credit agreement.

OPERATING ACTIVITIES

Net cash used in operations for the three months ended March 31, 2003 amounted to \$1,520,000. This amount arose primarily from the net loss of \$2,191,000, offset by non-cash charges of \$119,000 from the utilization of prepaid services and \$217,000 related to our share of the loss from our unconsolidated affiliate.

INVESTING ACTIVITIES

For the three months ended March 31, 2003, investing activities

## Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

provided cash in the amount of \$370,000, primarily from the liquidation of temporary cash investments.

### FINANCING ACTIVITIES

In January and March 2003, we completed private placement transactions in which we issued a total of 4,166,667 shares of common stock and warrants for the purchase of an additional 4,333,333 shares of common stock for aggregate proceeds of \$500,000. The warrants have an exercise price of \$0.15 per share and are exercisable at any time through March 31, 2007.

In March 2003, the Company and DNA-CS entered into a revolving line of credit with a bank in order to provide working capital to DNA-CS. Under the facility, DNA-CS may borrow up to \$1,000,000. Outstanding amounts are due March 26, 2004; however, DNA-CS may extend the maturity date six months, provided certain conditions are maintained. Interest is payable monthly at the greater of prime plus 1% and 5.25%. At March 31, 2003 \$600,000 was outstanding under this facility. This working capital facility is secured by the accounts receivable and inventory of DNA-CS, the guarantee of the Company and by limited guarantees provided by certain private investors. As consideration for providing the guarantees that secure the facility the Company has entered into a Reimbursement Agreement with the guarantors. The Reimbursement Agreement provides that the Company will reimburse the investors for any amounts that may be required to reimburse the bank pursuant to the guarantees. Pursuant to the Reimbursement Agreement and related agreements, the investors have the right to purchase up to 8,333,333 shares of the Company's common stock for \$1,000,000 in cash, and the proceeds will be used to repay amounts outstanding under the facility and provide for the release of the guarantees. In addition, the investors have received warrants to purchase an aggregate of 9,582,334 shares of the Company's common stock at a price of \$0.15 per share. The warrants may be exercised at any time through March 31, 2007.

### LIQUIDITY OUTLOOK

We also have had a series of discussions with potential financial and strategic investors regarding additional financing activities. These activities might include the repayment of all or a portion of our currently outstanding debt, as well as providing us with additional working capital. These financing activities might include the issuance of convertible preferred stock or convertible debt securities. The discussions have not resulted in definitive agreements or arrangements to date and there is no assurance that any additional financing can be arranged on terms acceptable to all parties involved.

In connection with the financing activities described above, we have been negotiating amendments to our credit agreements with Bank One NA ("Bank One") and a private investor who has provided security to Bank One related to these agreements. Currently, the Company has \$1,500,000 outstanding under a Loan Agreement with Bank One that is secured by the guarantee of the private investor. This agreement has been amended to extend the maturity to July 31, 2003. In addition, the Company has outstanding \$2,700,000 under a Credit Agreement with Bank One that is secured by a letter of credit provided by this same private investor. Amounts outstanding under this

facility are due March 31, 2004, with periodic reductions beginning May 30, 2003. The Company, Bank One and the private investor are currently engaged in discussion to amend these agreements in order to extend the maturities of these obligations. These discussions have not yet been concluded and there is no

## Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

assurance that the Company will be able to reach agreements acceptable to all parties involved. If we are unable to reach agreements related to our debt obligations and if we are unable to obtain required additional working capital, it may have a material adverse effect on our operations.

Our estimate of capital needs is subject to a number of risks and uncertainties that could result in additional capital needs that have not been anticipated. An important aspect of our estimated capital requirements is our ability to begin to generate positive cash flow from operations. As discussed above, this in turn is dependent upon our ability to increase revenues from our defense electronics business, to generate adequate gross profit from those sales and to control other costs and expenses. Our capital needs could increase materially if any of our contingent liabilities are resolved adversely to the Company. In addition, we could require additional working capital if the defense electronics business increases more rapidly than we currently anticipate.

Potential sources of additional capital include the sale of additional debt or equity securities, other debt, such as bank debt, and the sale of assets. A sale of additional securities could result in dilution to existing common shareholders. There is no assurance that additional capital will be available under terms that are acceptable to us.

### CONTINGENT LIABILITIES

As discussed in "ITEM 3 - Legal Proceedings" in the Company's Annual Report on Form 10-K, the Company is exposed to certain contingent liabilities which, if resolved adversely to the Company, would adversely affect its liquidity, its results of operations, and/or its financial position.

### ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have outstanding debt at March 31, 2003 amounting to \$6,300,000 that bears interest at a variable interest rate. This interest is based on a widely used reference interest rate known as LIBOR. An increase of 50 basis points in LIBOR would result in an increase in our annual interest expense of \$31,500.

### ITEM 4 - CONTROLS AND PROCEDURES

a) Evaluation of Disclosure Controls and Procedures. The term "disclosure controls and procedures" is defined in Rule 13a-14(c) of the Securities Exchange Act of 1934, or the Exchange Act. This term refers to the controls and procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized and reported within required time periods. Our Chief Executive Officer and our Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures as of a date within 90 days before the filing of this quarterly report, and they have concluded that as of that date, our disclosure controls and procedures were effective at ensuring that required information will be disclosed on a timely basis in our reports filed under the Exchange Act.

b) Changes in Internal Controls. We maintain a system of internal controls that are designed to provide reasonable assurance that our books and records accurately reflect in all material respects our transactions and that our established policies and procedures are followed. There were no significant changes to our internal controls or in other factors that could significantly affect our internal controls subsequent to the date of their evaluation by our Chief Executive Officer and our Chief Financial Officer, involving any corrective actions with regard to significant deficiencies and material weaknesses.

## PART II - OTHER INFORMATION

## ITEM 2 - CHANGES IN SECURITIES AND USE OF PROCEEDS

In the first quarter of 2003 we issued a total of 5,166,667 shares of our common stock and warrants for the purchase of an additional 4,333,333 shares of common stock in a series of private placements. Proceeds to us from these transactions totaled \$620,000 and were used for working capital. The warrants have an exercise price of \$0.15 per share and may be exercised at any time through March 31, 2007. The Company's sales of common stock were exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended (the Securities Act), and pursuant to Rule 506 of Regulation D of the Securities Act. A Rule 506 exemption was available for these sales because the Company sold only to accredited investors; the Company did not solicit or advertise the sales; a restrictive legend was placed on each certificate issued describing the restrictions against resale; and a Form D was filed with the Securities and Exchange Commission and in each state where the individual investors reside.

In March 2003, the Company and DNA-CS entered into a revolving line of credit with a bank in order to provide working capital to DNA-CS. Under the facility, DNA-CS may borrow up to \$1,000,000. Outstanding amounts are due March 26, 2004; however, DNA-CS may extend the maturity date six months, provided certain conditions are maintained. Interest is payable monthly at the greater of prime plus 1% and 5.25%. At March 31, 2003 \$600,000 was outstanding under this facility. This working capital facility is secured by the accounts receivable and inventory of DNA-CS, the guarantee of the Company and by limited guarantees provided by certain private investors. As consideration for providing the guarantees that secure the Note the Company has entered into a Reimbursement Agreement with the guarantors. The Reimbursement Agreement provides that the Company will reimburse the investors for any amounts that may be required to reimburse the bank pursuant to the guarantees. Pursuant to the Reimbursement Agreement and related agreements, the investors have the right to purchase up to 8,333,333 shares of the Company's common stock for \$1,000,000 in cash, and the proceeds will be used to repay amounts outstanding under the Note and provide for the release of the guarantees. In addition, the investors have received warrants to purchase an aggregate of 9,582,334 shares of the Company's common stock at a price of \$0.15 per share. The warrants may be exercised at any time through March 31, 2007.

## ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K

A. Listed below are all Exhibits filed as part of this report.

Exhibit	Description of Exhibit
99.1	906 Certificate
99.2	906 Certificate

B. The Company has not filed any report on Form 8-K during the period covered by this Report, except as follows:

On January 15, 2003, we filed a Current Report on Form 8-K/A amending the Current Report on Form 8-K dated October 3, 2002, disclosing information under Item 5 and filing exhibits under Item 9.

Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

12

On March 25, 2003, we filed a Current Report on Form 8-K/A amending the Current Report on Form 8-K dated October 3, 2002, disclosing information under Item 5 and filing exhibits under Item 9.

On March 26, 2003 we filed a Current Report on Form 8-K dated March 26, 2003, disclosing information under Item 5 and filing exhibits under Item 9.

13

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TERAFORCE TECHNOLOGY CORPORATION.  
(Registrant)

Date: May 15, 2003 /s/ ROBERT P. CAPPS  
-----  
Robert P. Capps  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

Date: May 15, 2003 /s/ HERMAN M. FRIETSCH  
-----  
Herman M. Frietsch  
Chief Executive Officer and Director  
(Principal Executive Officer)

14

CERTIFICATIONS

I, Herman M. Frietsch certify that:

1. I have reviewed this quarterly report on Form 10-Q of TeraForce Technology Corporation;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

## Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: May 15, 2003

/s/ HERMAN M. FRIETSCH  
-----  
Herman M. Frietsch  
Chief Executive Officer

15

I, Robert P. Capps certify that:

1. I have reviewed this quarterly report on Form 10-Q of TeraForce Technology Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements



## Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: May 15, 2003

/s/ ROBERT P. CAPPS

-----  
Robert P. Capps  
Chief Financial Officer

### EXHIBIT INDEX

Exhibit	Description
---------	-------------

Edgar Filing: TERAFORCE TECHNOLOGY CORP - Form 10-Q

-----

-----

99.1

906 Certificate

99.2

906 Certificate